Rosemarie Didonato1, Nella Shapiro2, Tova Koenigsberg3, Timothy D'Alfonso4, Shabnam Jaffer5, Susan Fineberg1. 1. Department of Pathology, Montefiore Medical Center and the Albert Einstein College of Medicine, Bronx, NY, USA. 2. Montefiore Medical Center and The Eastchester Center for Cancer Care, Bronx, NY, USA. 3. Division of Breast Imaging, Montefiore Medical Center and the Albert Einstein College of Medicine, Bronx, NY, USA. 4. Weill Cornell Medical Center and Cornell Medical College, New York, NY, USA. 5. Breast Pathology, Mount Sinai Medical Center, New York, NY, USA.
Abstract
AIMS: Neoadjuvant chemotherapy (NAC) is often used to treat localised invasive breast cancer. Invasive mucinous carcinoma (IMC) is considered to be an indolent form of invasive breast cancer, and is rarely treated with NAC. We report the largest series of IMCs treated with NAC, and report a characteristic, but not well recognised, pattern of pathological response. METHODS AND RESULTS: Our series included seven patients with IMC treated with NAC. Three patients presented with locally advanced disease, three patients had tumours that were HER-2/neu-positive, and four patients had tumours with admixed mucinous and micropapillary features. Clinical and imaging assessment of response showed persistent and, in some cases, progressive disease, despite evidence of significant pathological response in these cases. Pathological assessment after NAC demonstrated marked reduction in tumour cellularity, but persistent space-occupying mucin pools, showing acellular mucin in one case, <1% tumour cellularity in three cases, and 5-10% cellularity in three cases in both the treated breast and axillary lymph nodes. CONCLUSIONS: Persistent mass-forming low-cellular or acellular mucin pools can result in discordant clinical, imaging and pathological findings in IMC treated with NAC.
AIMS: Neoadjuvant chemotherapy (NAC) is often used to treat localised invasive breast cancer. Invasive mucinous carcinoma (IMC) is considered to be an indolent form of invasive breast cancer, and is rarely treated with NAC. We report the largest series of IMCs treated with NAC, and report a characteristic, but not well recognised, pattern of pathological response. METHODS AND RESULTS: Our series included seven patients with IMC treated with NAC. Three patients presented with locally advanced disease, three patients had tumours that were HER-2/neu-positive, and four patients had tumours with admixed mucinous and micropapillary features. Clinical and imaging assessment of response showed persistent and, in some cases, progressive disease, despite evidence of significant pathological response in these cases. Pathological assessment after NAC demonstrated marked reduction in tumour cellularity, but persistent space-occupying mucin pools, showing acellular mucin in one case, <1% tumour cellularity in three cases, and 5-10% cellularity in three cases in both the treated breast and axillary lymph nodes. CONCLUSIONS: Persistent mass-forming low-cellular or acellular mucin pools can result in discordant clinical, imaging and pathological findings in IMC treated with NAC.
Authors: Hedde D Biesma; Tanya T D Soeratram; Karolina Sikorska; Irene A Caspers; Hendrik F van Essen; Jacqueline M P Egthuijsen; Aart Mookhoek; Hanneke W M van Laarhoven; Mark I van Berge Henegouwen; Marianne Nordsmark; Donald L van der Peet; Fabienne A R M Warmerdam; Maud M Geenen; Olaf J L Loosveld; Johanneke E A Portielje; Maartje Los; Daniëlle A M Heideman; Elma Meershoek-Klein Kranenbarg; Henk H Hartgrink; Johanna van Sandick; Marcel Verheij; Cornelis J H van de Velde; Annemieke Cats; Bauke Ylstra; Nicole C T van Grieken Journal: Gastric Cancer Date: 2022-02-07 Impact factor: 7.701
Authors: Emilia Marrazzo; Federico Frusone; Flavio Milana; Andrea Sagona; Wolfgang Gatzemeier; Erika Barbieri; Alberto Bottini; Giuseppe Canavese; Arianna Olga Rubino; Marco Gaetano Eboli; Carlo Marco Rossetti; Alberto Testori; Valentina Errico; Alessandro De Luca; Corrado Tinterri Journal: Breast Date: 2019-11-11 Impact factor: 4.380